Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Spinal Cord Injury-Pipeline Review, H1 2015

Spinal Cord Injury-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Spinal Cord Injury-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Spinal Cord Injury-Pipeline Review, H1 2015', provides an overview of the Spinal Cord Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Spinal Cord Injury and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 8

Global Markets Direct Report Coverage 8

Spinal Cord Injury Overview 9

Therapeutics Development 10

Pipeline Products for Spinal Cord Injury-Overview 10

Pipeline Products for Spinal Cord Injury-Comparative Analysis 11

Spinal Cord Injury-Therapeutics under Development by Companies 12

Spinal Cord Injury-Therapeutics under Investigation by Universities/Institutes 17

Spinal Cord Injury-Pipeline Products Glance 19

Clinical Stage Products 19

Early Stage Products 20

Spinal Cord Injury-Products under Development by Companies 21

Spinal Cord Injury-Products under Investigation by Universities/Institutes 25

Spinal Cord Injury-Companies Involved in Therapeutics Development 27

Acorda Therapeutics, Inc. 27

Asubio Pharma Co., Ltd. 28

Athersys, Inc. 29

Axerion Therapeutics, Inc. 30

BioArctic Neuroscience AB 31

Faron Pharmaceuticals Oy 32

FirstString Research, Inc. 33

Genervon Biopharmaceuticals, LLC 34

Grupo Ferrer Internacional, S.A. 35

Hemostemix Ltd 36

Histocell S.L. 37

Intellipharmaceutics International Inc. 38

K-Stemcell Co., Ltd. 39

Kadimastem Ltd. 40

Kringle Pharma, Inc. 41

Lipopharma Therapeutics SL 42

Lpath, Inc. 43

MandalMed, Inc. 44

Mapreg S.A.S. 45

Mitsubishi Tanabe Pharma Corporation 46

Neuralstem, Inc. 47

Neuronax SAS 48

Omeros Corporation 49

PharmatrophiX, Inc. 50

Pharmicell Co., Ltd. 51

Q Therapeutics, Inc. 52

Quark Pharmaceuticals, Inc. 53

Remedy Pharmaceuticals, Inc. 54

RhinoCyte, Inc. 55

SanBio, Inc. 56

Sirnaomics, Inc. 57

StemCells, Inc. 58

Stemedica Cell Technologies, Inc. 59

TissueGene, Inc. 60

Vertex Pharmaceuticals Incorporated 61

Vicore Pharma AB 62

Spinal Cord Injury-Therapeutics Assessment 63

Assessment by Monotherapy Products 63

Assessment by Combination Products 64

Assessment by Target 65

Assessment by Mechanism of Action 67

Assessment by Route of Administration 69

Assessment by Molecule Type 71

Drug Profiles 73

(buspirone + levodopa + carbidopa)-Drug Profile 73

ACTX-08-Drug Profile 75

Antibody to Inhibit RGM for Spinal Cord Injury-Drug Profile 76

AP-325-Drug Profile 77

AST-OPC-1-Drug Profile 78

Astrostem-Drug Profile 80

AX-007-Drug Profile 81

BA-277-Drug Profile 82

BA-434-Drug Profile 83

C-21-Drug Profile 84

Cell Therapy for Spinal Cord Injury-Drug Profile 86

Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury-Drug Profile 87

Cerecellgram-Spine-Drug Profile 88

CHEC-7-Drug Profile 89

CHEC-9-Drug Profile 90

chondroitinase ABC nanosphere-Drug Profile 92

cimaglermin alfa-Drug Profile 93

CLR-01-Drug Profile 95

CM-101-Drug Profile 97

Drug for Spinal Cord Injury-Drug Profile 99

Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury-Drug Profile 100

FIB-117-Drug Profile 101

glyburide-Drug Profile 102

GM-603-Drug Profile 104

HBN-1-Drug Profile 105

HC-016-Drug Profile 106

HuCNS-SC-Drug Profile 107

ICCN-100-Drug Profile 109

IMS-001-Drug Profile 110

IMS-002-Drug Profile 111

interferon beta-1a-Drug Profile 112

KP-100IT-Drug Profile 114

LM11A-31-Drug Profile 116

LPA-181-Drug Profile 117

Lpathomab-Drug Profile 118

MAP-4343-Drug Profile 119

MultiStem-Drug Profile 120

NCP-01-Drug Profile 123

Neural Stem Cells-Drug Profile 124

neurovitas-Drug Profile 126

NgR(310)ecto-Fc-Drug Profile 127

NRP-2945-Drug Profile 129

NSI-566-Drug Profile 131

NX-210-Drug Profile 133

Oligonucleotide for Central Nervous System and Metabolic Disorders-Drug Profile 134

Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury-Drug Profile 135

Peptides for Central Nervous System and Musculoskeletal Disorders-Drug Profile 136

pregabalin ER-Drug Profile 137

PT-00114-Drug Profile 138

Q-Cells-Drug Profile 139

Recombinant Protein for Spinal Cord Injury-Drug Profile 141

SB-618-Drug Profile 142

SB-623-Drug Profile 143

SC-0806-Drug Profile 145

siRNA for CNS Disorders-Drug Profile 147

Small Molecule to Antagonize GPR17 for Central Nervous System Disorders-Drug Profile 148

Small Molecules for Spinal Cord Injury-Drug Profile 149

Stem Cell Therapy for Acute Spinal Cord Injury-Drug Profile 150

Stem Cell Therapy for CNS Disorders-Drug Profile 151

Stem Cell Therapy for Neurodegenerative Disorders-Drug Profile 152

Stem Cell Therapy for Spinal Cord Injury-Drug Profile 154

Stem Cell Therapy for Spinal Cord Injury-Drug Profile 155

Stem Cell Therapy Program for Neurodegenerative Diseases-Drug Profile 156

STP-805-Drug Profile 157

SUN-13837-Drug Profile 158

Synthetic Peptide for Spinal Cord Injuries-Drug Profile 159

Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease-Drug Profile 160

Tenascin-C Fragments for Spinal Cord Injury-Drug Profile 161

TG-N-Drug Profile 163

UH-0113-Drug Profile 164

UH-0213-Drug Profile 165

VX-210-Drug Profile 166

Spinal Cord Injury-Recent Pipeline Updates 169

Spinal Cord Injury-Dormant Projects 204

Spinal Cord Injury-Discontinued Products 208

Spinal Cord Injury-Product Development Milestones 209

Featured News & Press Releases 209

Appendix 219

Methodology 219

Coverage 219

Secondary Research 219

Primary Research 219

Expert Panel Validation 219

Contact Us 219

Disclaimer 220

List of Tables

Number of Products under Development for Spinal Cord Injury, H1 2015 15

Number of Products under Development for Spinal Cord Injury-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Development, H1 2015 25

Products under Development by Companies, H1 2015 26

Products under Development by Companies, H1 2015 (Contd..1) 27

Products under Development by Companies, H1 2015 (Contd..2) 28

Products under Development by Companies, H1 2015 (Contd..3) 29

Products under Investigation by Universities/Institutes, H1 2015 30

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 31

Spinal Cord Injury-Pipeline by Acorda Therapeutics, Inc., H1 2015 32

Spinal Cord Injury-Pipeline by Asubio Pharma Co., Ltd., H1 2015 33

Spinal Cord Injury-Pipeline by Athersys, Inc., H1 2015 34

Spinal Cord Injury-Pipeline by Axerion Therapeutics, Inc., H1 2015 35

Spinal Cord Injury-Pipeline by BioArctic Neuroscience AB, H1 2015 36

Spinal Cord Injury-Pipeline by Faron Pharmaceuticals Oy, H1 2015 37

Spinal Cord Injury-Pipeline by FirstString Research, Inc., H1 2015 38

Spinal Cord Injury-Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015 39

Spinal Cord Injury-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 40

Spinal Cord Injury-Pipeline by Hemostemix Ltd, H1 2015 41

Spinal Cord Injury-Pipeline by Histocell S.L., H1 2015 42

Spinal Cord Injury-Pipeline by Intellipharmaceutics International Inc., H1 2015 43

Spinal Cord Injury-Pipeline by K-Stemcell Co., Ltd., H1 2015 44

Spinal Cord Injury-Pipeline by Kadimastem Ltd., H1 2015 45

Spinal Cord Injury-Pipeline by Kringle Pharma, Inc., H1 2015 46

Spinal Cord Injury-Pipeline by Lipopharma Therapeutics SL, H1 2015 47

Spinal Cord Injury-Pipeline by Lpath, Inc., H1 2015 48

Spinal Cord Injury-Pipeline by MandalMed, Inc., H1 2015 49

Spinal Cord Injury-Pipeline by Mapreg S.A.S., H1 2015 50

Spinal Cord Injury-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 51

Spinal Cord Injury-Pipeline by Neuralstem, Inc., H1 2015 52

Spinal Cord Injury-Pipeline by Neuronax SAS, H1 2015 53

Spinal Cord Injury-Pipeline by Omeros Corporation, H1 2015 54

Spinal Cord Injury-Pipeline by PharmatrophiX, Inc., H1 2015 55

Spinal Cord Injury-Pipeline by Pharmicell Co., Ltd., H1 2015 56

Spinal Cord Injury-Pipeline by Q Therapeutics, Inc., H1 2015 57

Spinal Cord Injury-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 58

Spinal Cord Injury-Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 59

Spinal Cord Injury-Pipeline by RhinoCyte, Inc., H1 2015 60

Spinal Cord Injury-Pipeline by SanBio, Inc., H1 2015 61

Spinal Cord Injury-Pipeline by Sirnaomics, Inc., H1 2015 62

Spinal Cord Injury-Pipeline by StemCells, Inc., H1 2015 63

Spinal Cord Injury-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 64

Spinal Cord Injury-Pipeline by TissueGene, Inc., H1 2015 65

Spinal Cord Injury-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 66

Spinal Cord Injury-Pipeline by Vicore Pharma AB, H1 2015 67

Assessment by Monotherapy Products, H1 2015 68

Assessment by Combination Products, H1 2015 69

Number of Products by Stage and Target, H1 2015 71

Number of Products by Stage and Mechanism of Action, H1 2015 73

Number of Products by Stage and Route of Administration, H1 2015 75

Number of Products by Stage and Molecule Type, H1 2015 77

Spinal Cord Injury Therapeutics-Recent Pipeline Updates, H1 2015 174

Spinal Cord Injury-Dormant Projects, H1 2015 209

Spinal Cord Injury-Dormant Projects (Contd..1), H1 2015 210

Spinal Cord Injury-Dormant Projects (Contd..2), H1 2015 211

Spinal Cord Injury-Dormant Projects (Contd..3), H1 2015 212

Spinal Cord Injury-Discontinued Products, H1 2015 213

List of Figures

Number of Products under Development for Spinal Cord Injury, H1 2015 15

Number of Products under Development for Spinal Cord Injury-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Products, H1 2015 25

Assessment by Monotherapy Products, H1 2015 68

Number of Products by Top 10 Targets, H1 2015 70

Number of Products by Stage and Top 10 Targets, H1 2015 70

Number of Products by Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Top 10 Routes of Administration, H1 2015 74

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 74

Number of Products by Top 10 Molecule Types, H1 2015 76

Number of Products by Stage and Top 10 Molecule Types, H1 2015 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acorda Therapeutics, Inc.

Asubio Pharma Co., Ltd.

Athersys, Inc.

Axerion Therapeutics, Inc.

BioArctic Neuroscience AB

Faron Pharmaceuticals Oy

FirstString Research, Inc.

Genervon Biopharmaceuticals, LLC

Grupo Ferrer Internacional, S.A.

Hemostemix Ltd

Histocell S.L.

Intellipharmaceutics International Inc.

K-Stemcell Co., Ltd.

Kadimastem Ltd.

Kringle Pharma, Inc.

Lipopharma Therapeutics SL

Lpath, Inc.

MandalMed, Inc.

Mapreg S.A.S.

Mitsubishi Tanabe Pharma Corporation

Neuralstem, Inc.

Neuronax SAS

Omeros Corporation

PharmatrophiX, Inc.

Pharmicell Co., Ltd.

Q Therapeutics, Inc.

Quark Pharmaceuticals, Inc.

Remedy Pharmaceuticals, Inc.

RhinoCyte, Inc.

SanBio, Inc.

Sirnaomics, Inc.

StemCells, Inc.

Stemedica Cell Technologies, Inc.

TissueGene, Inc.

Vertex Pharmaceuticals Incorporated

Vicore Pharma AB

Spinal Cord Injury Therapeutic Products under Development, Key Players in Spinal Cord Injury Therapeutics, Spinal Cord Injury Pipeline Overview, Spinal Cord Injury Pipeline, Spinal Cord Injury Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com